541 related articles for article (PubMed ID: 29220291)
1. Emerging Targeted and Immune-Based Therapies in Sarcoma.
Pollack SM; Ingham M; Spraker MB; Schwartz GK
J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
3. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
4. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract][Full Text] [Related]
5. Next frontiers in systemic therapy for soft tissue sarcoma.
Yen CC; Chen TW
Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
[TBL] [Abstract][Full Text] [Related]
6. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic approaches to sarcoma.
Burgess M; Tawbi H
Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
[TBL] [Abstract][Full Text] [Related]
10. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Sarcoma: Future Horizons.
Burgess M; Gorantla V; Weiss K; Tawbi H
Curr Oncol Rep; 2015 Nov; 17(11):52. PubMed ID: 26423769
[TBL] [Abstract][Full Text] [Related]
12. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
[TBL] [Abstract][Full Text] [Related]
13. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.
MartÃn-Broto J; Moura DS; Van Tine BA
Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077
[TBL] [Abstract][Full Text] [Related]
14. Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
[TBL] [Abstract][Full Text] [Related]
15. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
[TBL] [Abstract][Full Text] [Related]
16. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
Zhu MMT; Shenasa E; Nielsen TO
Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
[TBL] [Abstract][Full Text] [Related]
17. Immune Therapy for Sarcomas.
Anderson PM
Adv Exp Med Biol; 2017; 995():127-140. PubMed ID: 28321815
[TBL] [Abstract][Full Text] [Related]
18. Role of Virus-Directed Therapy in Soft Tissue Sarcoma.
Chaudhary H; D'Angelo S
Curr Treat Options Oncol; 2022 Mar; 23(3):404-414. PubMed ID: 35258792
[TBL] [Abstract][Full Text] [Related]
19. From vision to reality: deploying the immune system for treatment of sarcoma.
Wilky BA; Goldberg JM
Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
[TBL] [Abstract][Full Text] [Related]
20. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
Banks LB; D'Angelo SP
J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]